The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis
- PMID: 8223835
- DOI: 10.1007/BF00315495
The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis
Abstract
The disposition of oral paracetamol (1.0 g 3 times daily for 10 days) was studied in 6 patients with end-stage renal failure (creatinine clearance < 5 ml x min-1) maintained on haemodialysis 2 or 3 times per week. Blood was sampled daily for 10 days. The time of sampling depended on whether the patients were dialysed in the morning or afternoon but was always within 5 h of the last dose of paracetamol. On dialysis days samples were taken at the start of the session. The mean plasma concentration of paracetamol was 6.8 mg x l-1 after the first 24 h and subsequently varied little throughout the 10 days. Apparent steady-state plasma concentrations of 60.0 mg x l-1 and 54.5 mg x l-1 were reached for the glucuronide and sulphate conjugate of paracetamol respectively by the 2nd day of treatment with little variation throughout the remainder of the study. These steady-state concentrations of paracetamol glucuronide and sulphate were much lower than predicted. The steady-state plasma concentrations of the retained cysteine and mercapturate conjugates of paracetamol were low (5.7 and 3.7 mg x l-1, respectively) and there was no evidence of accumulation of these potentially toxic metabolites. It is not clear why regular dosing with paracetamol in haemodialysis patients did not cause the accumulation of paracetamol glucuronide or sulphate as predicted. There may be enterohepatic elimination of retained paracetamol conjugates or depletion of substrates such as inorganic sulphate during chronic dosing.
Similar articles
-
The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure.Eur J Clin Pharmacol. 1991;41(1):43-6. doi: 10.1007/BF00280104. Eur J Clin Pharmacol. 1991. PMID: 1782975
-
Paracetamol disposition and metabolite kinetics in patients with chronic renal failure.Eur J Clin Pharmacol. 1989;36(3):291-7. doi: 10.1007/BF00558162. Eur J Clin Pharmacol. 1989. PMID: 2744070
-
Paracetamol and its metabolites in saliva and plasma in chronic dialysis patients.Br J Clin Pharmacol. 1996 Jan;41(1):41-7. doi: 10.1111/j.1365-2125.1996.tb00157.x. Br J Clin Pharmacol. 1996. PMID: 8824692
-
Kinetics and metabolism of paracetamol and phenacetin.Br J Clin Pharmacol. 1980 Oct;10 Suppl 2(Suppl 2):291S-298S. doi: 10.1111/j.1365-2125.1980.tb01812.x. Br J Clin Pharmacol. 1980. PMID: 7002186 Free PMC article. Review.
-
[Pharmacologic basis for using paracetamol: pharmacokinetic and pharmacodynamic issues].Drugs. 2003;63 Spec No 2:5-13. Drugs. 2003. PMID: 14758786 Review. French.
Cited by
-
Acetaminophen clearance during ex vivo continuous renal replacement therapies.J Artif Organs. 2018 Jun;21(2):215-219. doi: 10.1007/s10047-017-1001-6. Epub 2017 Oct 23. J Artif Organs. 2018. PMID: 29063343
-
Assessing and Treating Chronic Pain in Patients with End-Stage Renal Disease.Drugs. 2018 Sep;78(14):1459-1479. doi: 10.1007/s40265-018-0980-9. Drugs. 2018. PMID: 30206801 Review.
-
Identification of the cerebral effects of paracetamol in healthy subjects: an fMRI study.Br J Pain. 2020 Feb;14(1):23-30. doi: 10.1177/2049463719854483. Epub 2019 Jun 4. Br J Pain. 2020. PMID: 32110395 Free PMC article.
-
Physiologically based modeling of the pharmacokinetics of acetaminophen and its major metabolites in humans using a Bayesian population approach.Eur J Drug Metab Pharmacokinet. 2016 Jun;41(3):267-80. doi: 10.1007/s13318-015-0253-x. Epub 2015 Jan 31. Eur J Drug Metab Pharmacokinet. 2016. PMID: 25636597
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous